valsartan has been researched along with Brain Vascular Disorders in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (33.33) | 18.2507 |
| 2000's | 1 (16.67) | 29.6817 |
| 2010's | 2 (33.33) | 24.3611 |
| 2020's | 1 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Jeong, HE; Kim, JS; Ko, H; Lim, MJ; Shin, JY; Yoo, YG | 1 |
| Chujo, M; Hashimoto, T; Ishigaki, M; Kohro, T; Yamazaki, T | 1 |
| Angeli, F; Reboldi, G; Verdecchia, P | 1 |
| Bönner, G; Heintz, D; Kandra, A; Khder, Y; Malacco, E; Ruilope, LM | 1 |
| Hayashi, N; Inukai, T; Kometani, M; Nakao, K; Yamamoto, S | 1 |
| Barclay, BW; Navarrete, AE; Sahota, P; Webb, RL; Wosu, NJ | 1 |
1 trial(s) available for valsartan and Brain Vascular Disorders
| Article | Year |
|---|---|
Efficacy and tolerability of combination therapy with valsartan plus hydrochlorothiazide compared with amlodipine monotherapy in hypertensive patients with other cardiovascular risk factors: the VAST study.
Topics: Age Factors; Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Cerebrovascular Disorders; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Hydrochlorothiazide; Hypercholesterolemia; Hypertension; Male; Middle Aged; Myocardial Infarction; Obesity; Risk Factors; Tetrazoles; Valine; Valsartan | 2005 |
5 other study(ies) available for valsartan and Brain Vascular Disorders
| Article | Year |
|---|---|
Risk of myocardial infarction, heart failure, and cerebrovascular disease with the use of valsartan, losartan, irbesartan, and telmisartan in patients.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Biphenyl Compounds; Cerebrovascular Disorders; Heart Failure; Humans; Irbesartan; Losartan; Myocardial Infarction; Retrospective Studies; Telmisartan; Tetrazoles; Valsartan | 2023 |
The occurrence rate of cerebrovascular and cardiac events in patients receiving antihypertensive therapy from the post-marketing surveillance data for valsartan in Japan (J-VALID).
Topics: Aged; Angina Pectoris; Angiotensin Receptor Antagonists; Antihypertensive Agents; Cardiovascular Diseases; Cerebral Hemorrhage; Cerebral Infarction; Cerebrovascular Disorders; Female; Health Surveys; Heart Failure; Humans; Hypertension; Incidence; Japan; Male; Middle Aged; Myocardial Infarction; Product Surveillance, Postmarketing; Prospective Studies; Registries; Retrospective Studies; Stroke; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2013 |
Hypertension and the J-curve phenomenon: implications for tight blood pressure control.
Topics: Antihypertensive Agents; Cardiovascular Diseases; Cerebrovascular Disorders; Female; Humans; Hypertension; Male; Product Surveillance, Postmarketing; Tetrazoles; Valine; Valsartan | 2013 |
Pharmacological profile of valsartan, a non-peptide angiotensin II type 1 receptor antagonist. 2nd communication: valsartan prevents end-organ damage in spontaneously hypertensive stroke-prone rats during 1-year treatment.
Topics: Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Aorta, Thoracic; Blood Pressure; Body Weight; Cardiomegaly; Cerebrovascular Disorders; Enalapril; Heart Rate; Hypertension; Male; Mesentery; Muscle Contraction; Organ Size; Rats; Rats, Inbred SHR; Rats, Wistar; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Tetrazoles; Valine; Valsartan | 1997 |
Protective effects of valsartan and benazeprilat in salt-loaded stroke-prone spontaneously hypertensive rats.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Benzazepines; Blood Pressure; Cerebrovascular Disorders; Genetic Predisposition to Disease; Heart Rate; Hypertension; Infusion Pumps; Kidney; Myocardium; Proteinuria; Rats; Rats, Inbred SHR; Renin; Renin-Angiotensin System; Sodium Chloride; Tetrazoles; Valine; Valsartan | 1998 |